Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Director/PDMR Shareholding

4 Sep 2006 17:31

ReNeuron Group plc04 September 2006 NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY OR CONNECTED PERSONS This form is intended for use by an issuer to make a RIS notification requiredby DR 3.1.4R(1). (1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.(2) An issuer making a notification in respect of a derivative relating to the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24. (3) An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24. (4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. Please complete all relevant boxes in block capital letters. 1. Name of the issuer RENEURON GROUP PLC 2. State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.4R(1)(a); or (ii) DR 3.1.4(R)(1)(b) a disclosure made in accordance with section 324 (as extended by section 328) of the Companies Act 1985; or (iii) both (i) and (ii) (ii) 3. Name of person discharging managerial responsibilities/director MICHAEL HUNT 4. State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person DIRECTOR 5. Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest 6. Description of shares (including class), debentures or derivatives or financial instruments relating to shares 7. Name of registered shareholders(s) and, if more than one, the number of shares held by each of them 8. State the nature of the transaction 9. Number of shares, debentures or financial instruments relating to shares acquired 10. Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage) 11. Number of shares, debentures or financial instruments relating to shares disposed 12. Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage) 13. Price per share or value of transaction 14. Date and place of transaction 15. Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage) 16. Date issuer informed of transaction If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes 17. Date of grant 31 AUGUST 2006 18. Period during which or date on which it can be exercised DURING THE 10 YEAR PERIOD FROM THE DATE OF GRANT 19. Total amount paid (if any) for grant of the option NIL 20. Description of shares or debentures involved (class and number) OPTION OVER 500,000 ORDINARY SHARES 21. Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise 250,000 OPTIONS AT 10P PER SHARE 250,000 OPTIONS AT 15P PER SHARE 22. Total number of shares or debentures over which options held following notification OPTIONS OVER 2,400,000 ORDINARY SHARES AND WARRANTS OVER 29,500 ORDINARY SHARES 23. Any additional information 24. Name of contact and telephone number for queries MICHAEL HUNT, CEO 01483 302 560 Name and signature of duly authorised officer of issuer responsible for making notification Date of notification 4 SEPTEMBER 2006 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
2nd Sep 20247:00 amRNSCancellation - ReNeuron Group Plc
30th Aug 20247:00 amRNSCorporate update and AIM cancellation
2nd Aug 202412:25 pmRNSCorporate Update
26th Jun 20243:33 pmRNSChange of Registered Address
5th Jun 20243:36 pmRNSCreditor’s decision on Administrators' Proposals
17th May 202412:45 pmRNSPublication of Joint Administrators' Proposals
8th May 20247:00 amRNSUpdate on Administration Process
17th Apr 202411:30 amRNSDirectorate Change
20th Mar 20243:43 pmRNSAppointment of Administrators
20th Mar 202412:30 pmRNSIntention to Appoint Administrators
1st Mar 20247:00 amRNSBlock Listing Review & Total Voting Rights
5th Feb 20242:30 pmRNSSuspension - ReNeuron Group plc
5th Feb 20242:30 pmRNSCorporate update and suspension of trading on AIM
27th Nov 20238:53 amEQSEdison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™
8th Nov 20237:01 amRNSInterim Results for the six months ended 30 Sept
8th Nov 20237:00 amRNSReNeuron presents in vivo data at Cell 2023
4th Sep 20237:00 amRNSR&D Update
1st Sep 20237:00 amRNSBlock Listing Review & Total Voting Rights
29th Aug 20237:00 amRNSDirector declaration
22nd Aug 202310:34 amRNSResult of AGM
24th Jul 20235:20 pmRNSNotice of AGM
12th Jul 202311:57 amRNSShare Purchase by Chief Financial Officer
16th Jun 20235:12 pmRNSShare Purchase by Senior Independent NED
16th Jun 20232:26 pmRNSShare Purchase by Executive Chairman
16th Jun 20237:00 amRNSPosting of Annual Report & Accounts
5th Jun 20234:30 pmRNSHolding(s) in Company
25th May 20237:00 amRNSUnaudited Preliminary Results
18th May 20237:00 amRNSNotice of Results
17th May 20238:56 amRNSHolding(s) in Company
27th Apr 20238:18 amRNSHolding(s) in Company
6th Apr 20234:17 pmRNSShare Purchase by Senior Independent NED
3rd Apr 20237:00 amRNSNew Scientific Advisory Board
28th Mar 20232:23 pmRNSDirector/PDMR Shareholding
23rd Mar 20237:00 amRNSChange of adviser
13th Mar 20237:00 amRNSReNeuron to present at Advanced Therapies 2023
9th Mar 20234:03 pmRNSHolding(s) in Company
3rd Mar 20239:37 amRNSShare Purchase by Chief Financial Officer
1st Mar 20237:01 amRNSBlock listing application
1st Mar 20237:00 amRNSBlock Listing Review & Total Voting Rights
24th Feb 202311:20 amRNSDirector Share Purchases
15th Feb 20237:00 amRNSGrant of Options
30th Jan 20234:38 pmRNSDirector/PDMR Shareholding
27th Jan 202311:05 amRNSSecond Price Monitoring Extn
27th Jan 202311:00 amRNSPrice Monitoring Extension
24th Jan 202310:55 amRNSShare Purchase by Chief Financial Officer
23rd Jan 20233:04 pmRNSShare Purchase by Executive Chairman
19th Jan 20237:00 amRNSCompany restructuring update
3rd Jan 20237:02 amRNSTotal Voting Rights
3rd Jan 20237:00 amRNSDirectorate Change
12th Dec 20222:31 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.